

## Hull and East Riding Prescribing Committee Minutes – Confirmed

<b>Date / Time</b>	Wednesday 28 <sup>th</sup> April 2018
<b>Venue</b>	Seminar Room 1 Queens Centre for Oncology, Castle Hill Hospital
<b>Chair</b>	Dr S Raise, GP Prescribing Lead, ER
<b>Notes / Action Points</b>	Mrs W Hornsby, Senior Pharmacy Technician HEY.
<b>Quorate: Yes / No</b>	Yes

Mr K McCorry, Senior Pharmacist, ERY, NECS  
Mr A Ramirez, Senior Principal Pharmacist- Interface HEY  
Prof A Morice, Professor of Respiratory Medicine  
Mr J Ledger, Medicines Optimisation Pharmacy, CCG  
Dr R Schreiber, Medical Secretary, LMC  
Mr S Gaines, Senior Principal Pharmacist, HEY  
Mrs J Clarke Chief Officer Local Pharmaceutical Committee ERHLPC (until 2pm)  
Mrs J Stark, Principal Pharmacist, HTFT  
Mrs E Baguely, Senior Pharmacist, CHCP

<b>Apologies</b>	Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics, HEY Mr P Davis, Head Of Primary Care, Hull, CCG Prof M Lind, Professor of Oncology, HEY Mrs J Moore, Non-Medical Prescribing Lead/Medicines Optimisation Lead, HTFT Dr W Chong, Chief Pharmacist, HTFT Dr K Raghunath, GP Prescribing Lead, Hull CCG Mr G Hill, Principal Pharmacist, CHCP
------------------	---

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
2018.04.01	Apologies	As above.				
2018.04.02	Declarations of Interest	None.				
2018.04.03	Minutes of the previous meeting	Accepted as a true record.  Regarding the tofacinib question, the committee agreed that if a drug has a NICE TA can be used under the terms after 90 days. If it's requested before 90 days an IFR will be needed				
2018.04.04	Action Tracker	<p><b>SCF The Treatment and Management of Dementia</b> SCF approved</p> <p>Feedback on pilot to be discussed at next meeting</p> <p><b>Paediatric Growth Hormone SCF</b> KM informed that the commissioning arrangements have been agreed: HEY can recharge cost difference of drugs. AR to liaise with HEY finance team to confirm. Then to draft a plan for repatriation with paediatric team</p> <p><b>Biphosphonates as Supportive Therapy for Breast Cancer</b> No feedback from oncology as yet. New Action: Committee agreed that AR would draft a guideline</p> <p><b>Diabetes Formulary GLP-1 Agonists</b> The guideline is now on its 5<sup>th</sup> version. AR to chase it up</p>	<p>Action complete</p> <p>Feedback on pilot still required</p> <p>AR to draft guideline</p> <p>AR to discuss with endocrinology</p>	<p>Confirm agreement Draft plan</p> <p>For MMIG first</p> <p>For MMIG first</p>	<p>AR</p> <p>Kmc</p> <p>AR</p> <p>AR</p> <p>AR</p>	<p>4/18</p> <p>05/18</p> <p>05/18</p> <p>05/18</p> <p>05/18</p>

		<p><b>Guideline Gonadotrophin &amp; Gonadorelin from treatment of Prostate Cancer</b> SCF for degarelix has been circulated and is on agenda for discussion</p>	Action complete	Action complete		
		<p><b>Roflumilast for Treating Chronic Obstructive Pulmonary Disease</b> Already included on the COPD pathway so it's guideline led. No need to write a separate SCF</p>	Guideline led	No further action	AR	04/18
		<p><b>Fluticasone Furoate and Vilanterol (Relvar Ellipta)</b> Pathway is on agenda for discussion</p>	Discuss on agenda	No further action	AR	04/18
		<p><b>Adult Renal Transplant GP Prescribing</b> Awaiting answer from LMC</p>	RS to forward LMC comments to AR		RS	05/18
		<p><b>SOP for Administration of Red and Amber Drugs within Integrated Community Care Services</b> Website updated action complete</p>	Action complete	No further action	AR	4/18
		<p><b>Primary/Secondary Care Agreement</b> Document has been circulated to all parties for information</p>	Action complete	No further action		5/18
		<p><b>Flash Glucose Monitoring Systems</b> Website has been updated</p>	Action complete	No further action	EB/SG	4/18
		<p><b>Guideline for the treatment of Rosacea</b> Updates have been added. On website</p>	Action complete	No further action		
		<p><b>Guidance for the use of Sodium Valproate and Valproic Acid in Females with child bearing potential</b> On agenda for further discussion, as national guidance has been issued</p>	See AOB for decision	Action no longer relevant		
		<p><b>Guideline on Prescribing Gonadorelin Analogues and Progesterone Receptor Modulators in Treatment of Endometriosis, Uterine Fibroids (including Pre-op Use) or prior to endometrial ablation</b></p>	See correspondence received for decision	Action no longer relevant		

		<p>On agenda for discussion due to recent safety alert</p> <p><b>Clinical Guideline on the use of High Potency Vitamin D Replacement (and updated Denosumab SCF)</b> Re-circulated with amendments</p> <p><b>Guidelines for Treatment of Infections in Primary Care in Hull and East Riding</b> Updates on UTI area have been made and guideline has been added to website</p> <p><b>Prescribing Framework for Modafanil for Daytime Hypersomnolence</b> Document has been reformatted and added to website</p> <p><b>Diabetes Mellitus – Traditional Diagnostic Criteria</b> Updated and on website</p> <p><b>Oral Nutrition Supplements Flowchart</b> Approved. For Web</p> <p><b>DMARD prescribing Shared Care Agreement</b> DMARDs letter layout agreed with info to GPs about test results and advice to patient. AR to liaise with all relevant areas for them to use it</p> <p>AR explained that the Dermi and Gastro Pathways are in development. Dermi needs adding the new drugs just approved by D&amp;T.</p>	<p>Approved pending CCG</p> <p>Action complete</p> <p>Action Complete</p> <p>Action complete</p> <p>Action Complete</p> <p>Approved</p> <p>Share pathways with HERPC</p>	<p>No further action</p> <p>AR to communicate action</p>	<p>AR</p>	<p>5/18</p>
2018.04.05	Traffic Light Status	<p>Brodalumab – Approved as RED as an additional option for psoriasis patients where other biological treatments have not worked or are not tolerated.</p> <p>Carfilzomib – Approved as RED in line with NICE TA 457</p> <p>Nivolumab – Approved as RED in line with NICE TA462</p> <p>Sarilumab – Approved as RED in line with NICE TA 485</p>	<p>Noted</p>	<p>WH to update RED list</p>	<p>WH</p>	<p>5/18</p>

2018.04.06	Feedback From Commissioning Groups	Nothing to feedback	No action required			
2018.04.07	Prescribing guidelines, shared care frameworks for approval	<p><b>Type 2 diabetes Hba1c Targets</b> Approved to be added to website</p> <p><b>SCF Degarelix</b> The committee agreed the following changes “phlebotomy required by specialist” to be changed to “Specialist can request phlebotomy from GP” Updated document to be circulated to CCG. KM to find out it’s on reimbursement list</p> <p><b>Guideline on use of Unlicensed Medicines in Primary Care</b> GMC advice updated in line with guidance</p> <p><b>Medicines for Stroke Prevention in AF. Patient decision aid.</b> Document has been reformatted and updated to include Edoxaban. Warfarin information to be altered to “long term safety established”</p> <p><b>Treatment Algorithm for Adult Asthma/COPD Pathway</b> Approved, website to be updated</p> <p><b>Dementia Guideline</b> Agreed with amendments, KM to take to clinical policy subgroup and will email AR if it is approved to go on website</p> <p><b>SCF Verapamil in cluster headache</b> Approved add to website</p>	<p>Approved</p> <p>Approved with update</p> <p>Approved</p> <p>Approved with amendments</p> <p>Approved</p> <p>Approved</p> <p>Approved</p>	<p>Update website</p> <p>AR to send updated version to KMc</p> <p>Update website</p> <p>AR to update WH to add to website</p> <p>WH to update website</p> <p>KM to feedback to AR</p> <p>WH to update website</p>	<p>WH</p> <p>AR KM</p> <p>WH</p> <p>AR/WH</p> <p>WH</p> <p>KM</p> <p>WH</p>	<p>4/18</p> <p>5/18</p> <p>4/18</p> <p>5/18</p> <p>5/18</p> <p>5/18</p> <p>5/18</p>

		<p><b>SCF Lithium in Affective Disorders and Cluster Headaches</b> Approved add to website.</p> <p>AR mentioned that some GP's had been sending SCF back to him and not the specialists requesting it. Members mentioned that as it's a secretarial job they might be overlooking the instructions in the front page</p> <p><b>Ocular Lubricant Guideline</b> Approved. AR to circulate guideline to local LOC.</p>	<p>Approved</p> <p>AR to look into updating template</p> <p>Approved</p>	<p>WH to update website</p> <p>AR to send to LOC. SR to add to hot topics</p>	<p>WH</p> <p>AR</p> <p>AR</p> <p>SR</p>	<p>5/18</p> <p>7/18</p> <p>5/18</p>
	<b>Terms of Reference</b>	<p>The terms of reference were reviewed and agreed with the following updates: HFT to be altered to HTFT "service redesign &amp; planning" to be named as "clinical policy subgroup" "quality performance and finance committee" to be altered to ERCCG. Hull prescribing subcommittee to be removed CSU treatment advisory group to be removed</p>	AR to update	WH to add to website	AR WH	5/18
<b>2018.04.08</b>	<b>Correspondence Received</b>	<p><b>Supporting Guidance for Promoting Enriched SCR's</b> Documents attached by NHS Digital and MSO about lack of secondary and tertiary prescribed drugs on GP's SCR. GPs should be informed and have a record but doesn't show. Those drugs might have a great impact when patients admitted to hospital and aren't listed on SCR. NHS Digital guideline should solve the problem if followed although might be linked to Enhanced SCR. AR to attend NHS digital meeting as a guest to discuss and will feedback at July HERPC</p>	AR will attend NHS digital meeting	AR to feedback	AR	7/18

		<p><b>HEY Systemic Biological Therapy for Rheumatoid Arthritis</b> Although infliximab is a biosimilar and cheaper now it's not used first line so move to second line box.</p> <p><b>MHRA Esmya Alert</b> After the safety alert publication the guideline has been removed from the website. Committee agreed to remove Esmya section of guideline and replace with "Esmya Do Not Use – Await further instruction". Guideline can then be returned to website.</p> <p><b>Antibiotic Guidelines in Primary Care</b> AR received question about CAP not following NICE. Committee unsure of why. Dr Barlow has been unable to answer. AR to enquire again and modify accordingly.</p> <p><b>GMC response to new NICE guidance on treating eye conditions</b> Noted</p> <p><b>Revised National Guidance on Responsibilities for Prescribing between Primary and Secondary/Tertiary care</b> Noted</p>	<p>AR will liaise update with rheumatology</p> <p>Guideline to be amended</p> <p>Modify if needed</p> <p>Noted no action required</p> <p>Noted no action required</p>	<p>WH to add to website</p> <p>AR to update and WH to add to website</p>	<p>AR/WH</p> <p>AR/WH</p> <p>AR</p>	<p>7/18</p> <p>5/18</p> <p>5/18</p>
2018.04.09	Primary Care Rebate Scheme – Standing Item	No items to discuss				
2018.04.10	Additional Minutes for Information	<p>a) MMIG Jan</p> <p>b) HEY D&amp;T Jan /Feb</p> <p>c) HFTH DTC</p> <p>d) CHCP (none)</p>	Noted	No further action		
2018.04.11	A.O.B.	<b>Sodium Valproate &amp; Valproic Acid in childbearing females</b>	Alert to be added to website	WH to update website	WH	5/18

		<p>New alert published. Switch our own guidance in website for MHRA alert</p> <p><b>Brivaracetam</b> Agreed as a RED drug in July 17 with aim to make it green. AR to review prescribing at HEY. Then re-evaluate</p> <p><b>HEY D&amp;T</b> SG raised the need for a CCG representative to attend HEY D&amp;T meetings. KM &amp; SR to source a representative.</p> <p><b>Glucodrate</b> SG informed the committee that the licensed product Glucodrate had been discontinued so would be removed from the formulary. Two alternatives are still available: double dioralite and St Marks solution</p>	<p>Prescribing figures to be reviewed</p> <p>CCG rep to be sought</p> <p>Noted no further action</p>		<p>AR</p> <p>KMc/SR</p>	<p>5/18</p> <p>5/18</p>
2018.04.12	<b>Date and Time of Next Meeting</b>	<p>Wednesday 30th May 2018 1pm – 3pm, Board Room, Health House, Willerby, Hull</p>				